Head and Neck Squamous Cell Carcinoma
5 competing products in clinical development for Head and Neck Squamous Cell Carcinoma.
Pipeline by Phase
Phase 23
Phase 32
All Products (5)
| Product | Company | Stage | Status | Hype |
|---|---|---|---|---|
| Cemiplimab + Cetuximab | Eli Lilly | Phase 2 | Recruiting | 42 |
| Lenvatinib + Pembrolizumab + Placebo | Eisai | Phase 3 | Completed | 40 |
| Lenvatinib + Pembrolizumab + Placebo | Eisai | Phase 3 | Completed | 40 |
| Gemcitabine + ACR-368 | Acrivon Therapeutics | Phase 2 | Recruiting | 32 |
| BB-401 | Benitec Biopharma | Phase 2 | Completed | 25 |